ADTX - Aditx Therapeutics Inc Stock Price, Fair Value and News

$0.34-0.01 (-2.86%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ADTX Price Action

Last 7 days

-2.9%

Last 30 days

-68.8%

Last 90 days

-99.1%

Trailing 12 Months

-99.7%

ADTX RSI Chart

ADTX Valuation

Market Cap

4.8M

Price/Earnings (Trailing)

-0.12

Price/Sales (Trailing)

11.46

EV/EBITDA

-0.12

Price/Free Cashflow

-0.35

ADTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ADTX Fundamentals

ADTX Revenue

Revenue (TTM)

422.4K

Rev. Growth (Yr)

-84.49%

Rev. Growth (Qtr)

-84.52%

ADTX Earnings

Earnings (TTM)

-40.4M

Earnings Growth (Yr)

28.38%

Earnings Growth (Qtr)

7.54%

ADTX Profitability

Operating Margin

-99.41%

EBT Margin

-9576.05%

Return on Equity

-907.31%

Return on Assets

-135.28%

Free Cashflow Yield

-288.01%

ADTX Investor Care

Shares Dilution (1Y)

128759.82%

Diluted EPS (TTM)

528.93

ADTX Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	636.4K	459.7K	422.4K	0
2023	859.9K	866.2K	587.2K	775.2K
2022	464.2K	593.4K	722.6K	851.8K
2021	0	0	0	335.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Aditx Therapeutics Inc

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

CEO	Mr. Amro A. Albanna
WEBSITE	aditxt.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	61

Aditx Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aditx Therapeutics Inc? What does ADTX stand for in stocks?

ADTX is the stock ticker symbol of Aditx Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aditx Therapeutics Inc (ADTX)?

As of Wed Nov 20 2024, market cap of Aditx Therapeutics Inc is 4.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADTX stock?

You can check ADTX's fair value in chart for subscribers.

Is Aditx Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ADTX is over valued or under valued. Whether Aditx Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aditx Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADTX.

What is Aditx Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, ADTX's PE ratio (Price to Earnings) is -0.12 and Price to Sales (PS) ratio is 11.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADTX PE ratio will change depending on the future growth rate expectations of investors.